47%
Projected increase in new global cancer cases by 2040.
Precision Oncology · Gulf Cooperation Council
Next-generation cancer medicines, built for Arab patients, born in the Gulf.
IO:TCR is developing TCR bispecific immunotherapies — the most advanced class of precision cancer medicine — to serve patients across the Gulf and around the world. Our founders bring direct experience in the research, development, and commercialisation of TCR-based therapies.
- FDA & EMA approved class
- >90% tumour proteome reach
- Gulf-rooted R&D
+143%
Projected rise in GCC cancer cases by 2040
USD 112B
Global cancer immunotherapy market by 2032
>90%
Of tumour proteins addressable with TCR bispecifics
Vision & Mission
A globally influential oncology biotech, born in the Gulf.
IO:TCR is a next-generation, precision oncology biotechnology company rooted in the Gulf Cooperation Council region. We aim to revolutionise global cancer treatment and address healthcare inequality by developing TCR bispecific immunotherapies — medicines with high specificity, low toxicity, and a proven path through global regulators.
We prioritise Arab cancer patients while accessing global markets, targeting high-prevalence cancers including lung, breast, and colorectal — and ensuring Arab patient needs and Arab cancer genetics are at the forefront of every programme we run.
Beyond medicines for Arab populations, we are building home-grown Gulf R&D capability — developing regional scientific expertise, infrastructure, and intellectual property designed to deliver both regional impact and global out-licensing reach.
Precision
Targeting cancer with the specificity of T cell receptors — not just cell-surface proteins.
Population-relevant
Designed with Arab HLA genetics in mind, while serving patients globally.
Proven class
Our Founders bring direct experience in the R&D and commercialisation of TCR therapies.
Our Platform
TCR Bispecifics — the next frontier of immunotherapy.
T cell Receptor (TCR) Bispecifics are a next-generation class of cancer immunotherapy. They guide the body’s own T cells to recognise and destroy cancer cells — including those that evade traditional therapies — by accessing previously inaccessible targets inside the cell.
-
>90% tumour proteome reach
Antibody drugs see <10% of cancer targets. TCR bispecifics unlock the rest — the intracellular world.
-
“Off-the-shelf” medicines
No personalised cell manufacture. Predictable supply, predictable cost.
-
Manageable safety profile
Engineered for high specificity and low toxicity — designed for global regulatory acceptance.
-
Clinically proven class
KIMMTRAK, the world’s first approved TCR bispecific, doubled survival in metastatic uveal melanoma.
The Opportunity
A rising tide of need — and a rare window of advantage.
+460%
Rise in cancer incidence among the over-70s in the GCC by 2040.
USD 450K
Per patient, per course of precision immunotherapy treatment.*
CAGR 16.5%
Cancer immunotherapy is one of the fastest-growing segments in healthcare.
*Reference: 6‑month course of KIMMTRAK (tebentafusp) in the USA.
Aligned with Gulf national visions
A strategic asset for the Gulf’s life-sciences ambitions.
IO:TCR is more than a pharmaceutical investment — we are a regional strategic asset aligned with the national visions of GCC member states. By building R&D, manufacturing, and clinical capability in the Gulf, we support national biotechnology strategies and help position the region as a global biotech hub.
Saudi Arabia
Vision 2030 · National Biotechnology Strategy
Biomanufacturing, genomics and vaccine localisation — with the ambition of becoming the leading biotech hub in MENA by 2030.
United Arab Emirates
We the UAE 2031 · Emirates Drug Establishment
Abu Dhabi’s HELM life-sciences cluster and the Emirati Genome Programme, alongside Dubai Science Park’s life-sciences community.
- High-value contribution to non-oil economic diversification
- Increased life expectancy and improved public health
- International knowledge transfer and localised scientific excellence
- Skilled employment for Gulf research and biotech graduates
- IP ownership anchored in the region
For Investors
Well positioned for early-stage growth.
We are advancing multiple precision cancer assets, building a Gulf biotech ecosystem, and generating IP designed for global out-licensing. Investor and partnership enquiries are welcome from qualified institutions, family offices, and sovereign capital.
Request more informationGet in Touch
We welcome your interest.
IO:TCR is currently operating in stealth. For partnership, investment, scientific collaboration, or media enquiries, please reach our central contact team.